Colorectal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for colorectal cancer in Western medicine, with imaging confirming TNM staging as unresectable IIIc or IV stage, and the treatment regimen is CapOx plus bevacizumab; 2. Has at least one measurable lesion; 3. Meets the diagnostic criteria for spleen deficiency with blood stasis and toxin syndrome in traditional Chinese medicine; 4. Expected survival period of more than 6 months, with Karnofsky performance status (KPS) score >60; 5. Age between 18 and 75 years; 6. Blood tests, liver and kidney function, and other indicators meet the criteria for chemotherapy; 7. Voluntarily participates in this study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with lesions that are resectable according to tumor TNM staging but unfit for surgery due to other reasons; 2. Patients with other severe primary diseases such as cardio-cerebrovascular, hepatic, renal, or hematopoietic system disorders; 3. Patients with allergic constitutions or hypersensitivity to the investigational drug; 4. Patients with intellectual disabilities, mental, or cognitive impairments that prevent cooperation; 5. Pregnant or breastfeeding women, or patients intending to conceive during the trial period; 6. Patients who have participated in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor markers (carcinoembryonic antigen, carbohydrate antigen CA19-9);T cell subsets; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life Rating;Solid Tumor Efficacy Evaluation Criteria;Traditional Chinese Medicine Syndrome Scoring; | — |
Countries
China
Contacts
Liaoning University of Traditional Chinese Medicine Affiliated Second Hospital